Pfizer/Agouron prinomastat

Pfizer halts Phase III trials of the selective matrix metalloprotease inhibitor due to unmet primary efficacy objectives for the treatment of advanced hormone refractory prostate cancer and stage IV non-small cell lung cancer. Four Phase II studies in other indications are continuing. Prinomastat was developed by Agouron, which was acquired by Warner-Lambert in 1999. Following the consolidation of Warner-Lambert into Pfizer, Agouron's research division is now known as "Pfizer Global Research & Development, La Jolla Laboratories"